Compugen introduces platform of genome, transcriptome, and proteome databases

At the annual Genome Sequencing and Analysis Conference in Miami Beach, Florida last week, Compugen Ltd. (Tel Aviv, Israel) introduced Gencarta, a comprehensive platform that provides access to Compugen's proprietary annotated genome, transcriptome, and proteome databases. Compugen expects that the subscription-based platform will be commercially available for installation at high throughput laboratories in the first quarter of 2001.

Gencarta gives researchers access to Compugen's proprietary LEADS transcriptome database. By applying LEADS analysis and data mining tools to various public and non-public databases, scientists can gain access to tens of thousands of predicted genes and splice variants, putative cSNPs, and annotated genomic information—all through a single data source.

In addition, Gencarta's viewers enable users to query and browse the genome, with access to data on several levels. The genomic level includes information concerning genes and pseudogenes, repeats, CpG islands, SNPs, enhancers, and promoters. The transcript level includes information regarding splice variants, aligned ESTs, and mRNAs. Each splice variant is then further annotated with information about homologues, SAGE-based expression profiles, open reading frames, sequence translation, and detailed domain summaries.

Compugen is computational genomics and proteomics company that develops proprietary, comprehensive platforms to improve and accelerate life science research. In addition, the company recently established a Novel Genomics division to commercialize, mainly through licensing arrangements, some of the genes and proteins that it discovers in its own research efforts.

For more information: Tsipi Haitovsky, Director, Corporate Communications, Compugen Ltd., 72 Pinchas Rosen St., Tel Aviv 69512, Israel. Tel: +972-3-7658120. Email: tsipi@cgen.com.

Edited by Jim Pomager
Assistant Editor, Bioresearch Online

Source: Compugen Ltd.